US physicians and others in the scientific sector are calling for the release of the complete trial findings that convinced the FDA to grant emergency use authorization to Gilead Sciences' antiviral drug remdesivir to treat COVID-19. "We want to direct the drug to those most likely to benefit and least likely to be harmed," Dr. Helen Boucher, chief of infectious diseases at Tufts Medical Center, said.
Physicians call for release of remdesivir trial data
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.